These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 19458008)

  • 61. Raltegravir: in treatment-naive patients with HIV-1 infection.
    Croxtall JD; Scott LJ
    Drugs; 2010 Mar; 70(5):631-42. PubMed ID: 20329808
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Response of a simian immunodeficiency virus (SIVmac251) to raltegravir: a basis for a new treatment for simian AIDS and an animal model for studying lentiviral persistence during antiretroviral therapy.
    Lewis MG; Norelli S; Collins M; Barreca ML; Iraci N; Chirullo B; Yalley-Ogunro J; Greenhouse J; Titti F; Garaci E; Savarino A
    Retrovirology; 2010 Mar; 7():21. PubMed ID: 20233398
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The Combination of the R263K and T66I Resistance Substitutions in HIV-1 Integrase Is Incompatible with High-Level Viral Replication and the Development of High-Level Drug Resistance.
    Liang J; Mesplède T; Oliveira M; Anstett K; Wainberg MA
    J Virol; 2015 Nov; 89(22):11269-74. PubMed ID: 26311878
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Virological evidence supporting the use of raltegravir in HIV post-exposure prophylaxis regimens.
    Marsden MD; Krogstad PA; Zack JA
    Antivir Ther; 2012; 17(7):1375-9. PubMed ID: 22820096
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Raltegravir dosage adjustment in HIV-infected patients receiving etravirine.
    Do VT; Higginson RT; Fulco PP
    Am J Health Syst Pharm; 2011 Nov; 68(21):2049-54. PubMed ID: 22011983
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Resistance associated mutations to dolutegravir (S/GSK1349572) in HIV-infected patients--impact of HIV subtypes and prior raltegravir experience.
    Garrido C; Soriano V; Geretti AM; Zahonero N; Garcia S; Booth C; Gutierrez F; Viciana I; de Mendoza C
    Antiviral Res; 2011 Jun; 90(3):164-7. PubMed ID: 21439330
    [TBL] [Abstract][Full Text] [Related]  

  • 67. In vivo evidence for instability of episomal human immunodeficiency virus type 1 cDNA.
    Sharkey M; Triques K; Kuritzkes DR; Stevenson M
    J Virol; 2005 Apr; 79(8):5203-10. PubMed ID: 15795303
    [TBL] [Abstract][Full Text] [Related]  

  • 68. A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase.
    Hazuda DJ; Anthony NJ; Gomez RP; Jolly SM; Wai JS; Zhuang L; Fisher TE; Embrey M; Guare JP; Egbertson MS; Vacca JP; Huff JR; Felock PJ; Witmer MV; Stillmock KA; Danovich R; Grobler J; Miller MD; Espeseth AS; Jin L; Chen IW; Lin JH; Kassahun K; Ellis JD; Wong BK; Xu W; Pearson PG; Schleif WA; Cortese R; Emini E; Summa V; Holloway MK; Young SD
    Proc Natl Acad Sci U S A; 2004 Aug; 101(31):11233-8. PubMed ID: 15277684
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Durable suppression of HIV-1 with resistance mutations to integrase inhibitors by dolutegravir following drug washout.
    Osman N; Mesplède T; Oliveira M; Hassounah S; Wainberg MA; Brenner BG
    AIDS; 2018 Aug; 32(13):1773-1780. PubMed ID: 29894388
    [TBL] [Abstract][Full Text] [Related]  

  • 70. No residual activity of raltegravir after development of 148 complex mutations in vivo.
    Khanlou H; Sayana S; Acosta E
    J Int Assoc Physicians AIDS Care (Chic); 2008; 7(6):281-2. PubMed ID: 19164138
    [No Abstract]   [Full Text] [Related]  

  • 71. Genetic barrier to the development of resistance to integrase inhibitors in HIV-1 subtypes CRF01_AE and B.
    Nguyen HL; Ruxrungtham K; Delaugerre C
    Intervirology; 2012; 55(4):287-95. PubMed ID: 22456540
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Raltegravir: an integrase inhibitor for HIV-1.
    Evering TH; Markowitz M
    Expert Opin Investig Drugs; 2008 Mar; 17(3):413-22. PubMed ID: 18321239
    [TBL] [Abstract][Full Text] [Related]  

  • 73. A combined genotypic and phenotypic human immunodeficiency virus type 1 recombinant virus assay for the reverse transcriptase and integrase genes.
    Van Baelen K; Rondelez E; Van Eygen V; Ariën K; Clynhens M; Van den Zegel P; Winters B; Stuyver LJ
    J Virol Methods; 2009 Nov; 161(2):231-9. PubMed ID: 19559730
    [TBL] [Abstract][Full Text] [Related]  

  • 74. HIV dynamics and integrase inhibitors.
    Murray JM
    Antivir Chem Chemother; 2009; 19(4):157-64. PubMed ID: 19374143
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The future of integrase inhibitors of HIV-1.
    Malet I; Calvez V; Marcelin AG
    Curr Opin Virol; 2012 Oct; 2(5):580-7. PubMed ID: 22980926
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Design, synthesis and SAR study of bridged tricyclic pyrimidinone carboxamides as HIV-1 integrase inhibitors.
    Patel M; Naidu BN; Dicker I; Higley H; Lin Z; Terry B; Protack T; Krystal M; Jenkins S; Parker D; Panja C; Rampulla R; Mathur A; Meanwell NA; Walker MA
    Bioorg Med Chem; 2020 Jul; 28(13):115541. PubMed ID: 32389483
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Characterization and structural analysis of HIV-1 integrase conservation.
    Ceccherini-Silberstein F; Malet I; D'Arrigo R; Antinori A; Marcelin AG; Perno CF
    AIDS Rev; 2009; 11(1):17-29. PubMed ID: 19290031
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Prevalence of primary resistance mutations to integrase inhibitors in treatment-naïve and -experienced patients infected with B and non-B HIV-1 variants.
    Gutiérrez C; Hernández-Novoa B; Pérez-Elías MJ; Moreno AM; Holguín A; Dronda F; Casado JL; Moreno S
    HIV Clin Trials; 2013; 14(1):10-6. PubMed ID: 23372110
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Early emergence of raltegravir resistance mutations in patients receiving HAART salvage regimens.
    Baldanti F; Paolucci S; Gulminetti R; Brandolini M; Barbarini G; Maserati R
    J Med Virol; 2010 Jan; 82(1):116-22. PubMed ID: 19950236
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The role of unintegrated DNA in HIV infection.
    Sloan RD; Wainberg MA
    Retrovirology; 2011 Jul; 8():52. PubMed ID: 21722380
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.